Rimegepant
- Generic Name
- Rimegepant
- Brand Names
- Nurtec, Vydura
- Drug Type
- Small Molecule
- Chemical Formula
- C28H28F2N6O3
- CAS Number
- 1289023-67-1
- Unique Ingredient Identifier
- 997WVV895X
- Background
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its re...
- Indication
Rimegepant is indicated for the acute treatment of migraine with or without aura in adults. Rimegepant is also indicated for the prevention of episodic migraine in adults.
- Associated Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
- Conditions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03934086
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1590
- Registration Number
- NCT03732638
- Locations
- ๐บ๐ธ
Cedar Crosse Research Center, Chicago, Illinois, United States
๐บ๐ธOklahoma Headache Center, Norman, Oklahoma, United States
๐บ๐ธClinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States
Trial in Adult Subjects With Acute Migraines
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1811
- Registration Number
- NCT03461757
- Locations
- ๐บ๐ธ
Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States
๐บ๐ธSundance Clinical Research, Saint Louis, Missouri, United States
๐บ๐ธKi Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States
Open Label Safety Study in Acute Treatment of Migraine
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3019
- Registration Number
- NCT03266588
- Locations
- ๐บ๐ธ
FutureSearch Trials of Neurology, LP, Dallas, Texas, United States
๐บ๐ธWoodland Research Northwest, LLC, Rogers, Arkansas, United States
๐บ๐ธClinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States
Safety and Efficacy in Adult Subjects With Acute Migraines
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1499
- Registration Number
- NCT03237845
- Locations
- ๐บ๐ธ
Radiant Research, Inc., Anderson, South Carolina, United States
๐บ๐ธSummit Research Network (Oregon), Inc., Portland, Oregon, United States
๐บ๐ธCoastal Clinical Research, Mobile, Alabama, United States
Safety and Efficacy Study in Adult Subjects With Acute Migraines
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1485
- Registration Number
- NCT03235479
- Locations
- ๐บ๐ธ
Neurological Physicians of Arizona/Radiant Research Inc, Gilbert, Arizona, United States
๐บ๐ธClinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States
๐บ๐ธClinical Research Institute, Minneapolis, Minnesota, United States
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1026
- Registration Number
- NCT01430442
- Locations
- ๐บ๐ธ
Broward Research Group, Pembroke Pines, Florida, United States
๐บ๐ธClinical Res. Advantage Inc/ Desert Clinical Research Llc, Tempe, Arizona, United States
๐บ๐ธTidewater Integrated Medical Research, Virginia Beach, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.